Skip to main content
. 2011 Jun 14;19(9):1737–1746. doi: 10.1038/mt.2011.113

Figure 3.

Figure 3

Administration of low-dose cyclophosphamide (CP) in combination with oncolytic adenoviruses did not impair antitumor and anti-adenovirus T-cell response. Interferon-γ (IFN-γ) ELISPOT analysis was performed on patients before and after treatment. (a) Adenovirus only (Ad); (b) Ad + metronomic CP per os; (c) Ad + CP single intravenous administration; (d) Ad + metronomic CP per os + single intravenous (i.v.) administration. SFU, spot forming units.